John G. Webb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John G. Webb has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
Janarthanan Sathananthan
St Pauls Hosp, Ctr Cardiovasc Innovat, Vancouver, BC, Canada
20 shared publicationsPhilipp Blanke
St Pauls Hosp, Ctr Cardiovasc Innovat, Vancouver, BC, Canada
20 shared publicationsDavid A. Wood
Centre for Cardiovascular Innovation, St. Paul's and Vancouver General Hospital, Vancouver, Canada; Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
18 shared publicationsAnson Cheung
Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
15 shared publicationsJonathon Leipsic
Centres for Heart Valve and Cardiovascular Innovation, St. Paul's and Vancouver General Hospital, Vancouver, British Columbia, Canada
11 shared publicationsMark Hensey
St. Paul's Hospital, Vancouver, British Columbia, Canada
11 shared publications
Latest Publications
- 23 February 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (4) , 514-516
Transcatheter Valve Implantation in Failed Mechanical Valves?
- 23 February 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (4) , 514-516
Transcatheter Valve Implantation in Failed Mechanical Valves?
- 23 February 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (4) , 532-534
Feasibility of Transcatheter Valve Implantation in Failed Mechanical Valves
- 23 February 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (4) , 532-534
Feasibility of Transcatheter Valve Implantation in Failed Mechanical Valves
- 23 June 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (12) , 1584-1586
Coronary Access Following TAVR
- 23 June 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (12) , 1584-1586
Coronary Access Following TAVR
- Open Access
Sex Differences in Newly Diagnosed Severe Aortic Stenosis in British Columbia (B.C.)
Background: Despite its high prevalence, little is known about the effect of sex on the management and outcomes of aortic stenosis (AS). We sought to characterize the effect of sex on the clinical evaluation for and provision of aortic valve replacement (AVR), including surgical (SAVR) and transcatheter aortic valve replacement (TAVR), and the subsequent morbidity and mortality outcomes. Methods: A comprehensive chart review was conducted on all patients with a first diagnosis of severe aortic stenosis (AS) at Vancouver General and University of British Columbia hospitals from 2012 to 2022. Exact chi-square and Kruskal–Wallis tests were used to evaluate the variables of interest. Results: A total of 1794 studies met the inclusion criteria, comprising 782 females (44%) and 1012 males (56%). Females were significantly older than males at the time of the first diagnosis (79 versus 75 years, p < 0.001). Females were significantly less likely to be evaluated by the TAVR clinic or cardiac surgeon or to receive aortic valve intervention (p-value ≤ 0.001). Females were significantly more likely to be rejected for TAVR due to older age (OR 0.23 (0.07, 0.59)), comorbid conditions (OR 0.68 (0.47, 0.97)), and frailty (OR 0.23 (0.07, 0.59)). Females were significantly more likely to be rejected for SAVR on the basis of frailty (OR 0.66 (0.46, 0.94)). Females also had significantly higher rates of 1-year mortality, hospitalization, and heart failure hospitalization compared to males (p-values < 0.05). Conclusions: Our data suggest significant sex-based discrepancies in the management of AS. Females with severe AS are diagnosed later in life and are less likely to be evaluated for valve intervention. They are less likely to receive intervention due to older age, frailty, and multimorbid conditions. Further research is warranted for a more effective identification and follow up of aortic stenosis, as well as timely referral for AVR, where appropriate, especially for females.
Open AccessSex Differences in Newly Diagnosed Severe Aortic Stenosis in British Columbia (B.C.)
Background: Despite its high prevalence, little is known about the effect of sex on the management and outcomes of aortic stenosis (AS). We sought to characterize the effect of sex on the clinical evaluation for and provision of aortic valve replacement (AVR), including surgical (SAVR) and transcatheter aortic valve replacement (TAVR), and the subsequent morbidity and mortality outcomes. Methods: A comprehensive chart review was conducted on all patients with a first diagnosis of severe aortic stenosis (AS) at Vancouver General and University of British Columbia hospitals from 2012 to 2022. Exact chi-square and Kruskal–Wallis tests were used to evaluate the variables of interest. Results: A total of 1794 studies met the inclusion criteria, comprising 782 females (44%) and 1012 males (56%). Females were significantly older than males at the time of the first diagnosis (79 versus 75 years, p < 0.001). Females were significantly less likely to be evaluated by the TAVR clinic or cardiac surgeon or to receive aortic valve intervention (p-value ≤ 0.001). Females were significantly more likely to be rejected for TAVR due to older age (OR 0.23 (0.07, 0.59)), comorbid conditions (OR 0.68 (0.47, 0.97)), and frailty (OR 0.23 (0.07, 0.59)). Females were significantly more likely to be rejected for SAVR on the basis of frailty (OR 0.66 (0.46, 0.94)). Females also had significantly higher rates of 1-year mortality, hospitalization, and heart failure hospitalization compared to males (p-values < 0.05). Conclusions: Our data suggest significant sex-based discrepancies in the management of AS. Females with severe AS are diagnosed later in life and are less likely to be evaluated for valve intervention. They are less likely to receive intervention due to older age, frailty, and multimorbid conditions. Further research is warranted for a more effective identification and follow up of aortic stenosis, as well as timely referral for AVR, where appropriate, especially for females.
- Open Access
- 28 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3794
Non-Invasive Hemodynamic Monitoring in Transcatheter Aortic Valve Implantation
Background/Objectives: Aortic valve stenosis (AS) is a prevalent cardiovascular condition among elderly patients frequently treated with Transcatheter Aortic Valve Implantation (TAVI). Traditional hemodynamic monitoring during TAVI relies on invasive methods. The ClearSight® Finger Cuff system offers a non-invasive alternative for continuous hemodynamic monitoring. To compare the reliability and feasibility of non-invasive hemodynamic monitoring with traditional invasive hemodynamic monitoring during TAVI procedures. Methods: In this prospective observational study, patients undergoing elective TAVI were recruited from two tertiary hospitals between March and August 2023. Invasive hemodynamic measurements were obtained using arterial and pigtail catheters, with a subset undergoing right heart catheterization. Non-invasive measurements were captured using the ClearSight® system. Data on baseline characteristics, procedural details, and 30-day follow-up outcomes were collected. Results: The study cohort comprised 50 patients (median age 82 years (IQR 78.0, 85.8), 50% female). Non-invasive measurements of cardiac output (CO), cardiac index (CI), and stroke volume (SV) were consistently lower than invasive measurements (CO: 4.1 vs. 4.8 L/min, p = 0.03; CI: 2.2 vs. 2.7 L/min/m2, p = 0.01, SV: 66 vs. 77 mL, p = 0.25). Non-invasive blood pressure readings were lower than invasive radial and aortic measurements before and after TAVI. Correlation of non- and invasive measurements was low but similar before and after TAVI (Mean percentage error of 52%). Conclusions: The ClearSight® system provided lower absolute values for all evaluated hemodynamic parameters as well as low correlation compared to traditional methods pre- as well as post-interventional.
- 28 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3794
Open AccessNon-Invasive Hemodynamic Monitoring in Transcatheter Aortic Valve Implantation
Background/Objectives: Aortic valve stenosis (AS) is a prevalent cardiovascular condition among elderly patients frequently treated with Transcatheter Aortic Valve Implantation (TAVI). Traditional hemodynamic monitoring during TAVI relies on invasive methods. The ClearSight® Finger Cuff system offers a non-invasive alternative for continuous hemodynamic monitoring. To compare the reliability and feasibility of non-invasive hemodynamic monitoring with traditional invasive hemodynamic monitoring during TAVI procedures. Methods: In this prospective observational study, patients undergoing elective TAVI were recruited from two tertiary hospitals between March and August 2023. Invasive hemodynamic measurements were obtained using arterial and pigtail catheters, with a subset undergoing right heart catheterization. Non-invasive measurements were captured using the ClearSight® system. Data on baseline characteristics, procedural details, and 30-day follow-up outcomes were collected. Results: The study cohort comprised 50 patients (median age 82 years (IQR 78.0, 85.8), 50% female). Non-invasive measurements of cardiac output (CO), cardiac index (CI), and stroke volume (SV) were consistently lower than invasive measurements (CO: 4.1 vs. 4.8 L/min, p = 0.03; CI: 2.2 vs. 2.7 L/min/m2, p = 0.01, SV: 66 vs. 77 mL, p = 0.25). Non-invasive blood pressure readings were lower than invasive radial and aortic measurements before and after TAVI. Correlation of non- and invasive measurements was low but similar before and after TAVI (Mean percentage error of 52%). Conclusions: The ClearSight® system provided lower absolute values for all evaluated hemodynamic parameters as well as low correlation compared to traditional methods pre- as well as post-interventional.
- 14 July 2024
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 69, 10-11
Editorial: Decreasing pacemaker implantation rates with Evolut supra-annular transcatheter aortic valves
- 14 July 2024
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 69, 10-11
Editorial: Decreasing pacemaker implantation rates with Evolut supra-annular transcatheter aortic valves
- 3 January 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (4) , 574-576
Transcatheter Mitral Valve-in-Valve Replacement in the Presence of Pannus
- 3 January 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (4) , 574-576
Transcatheter Mitral Valve-in-Valve Replacement in the Presence of Pannus
- 8 November 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (23) , 2920-2922
Transcatheter Mitral Valve Replacement
- 8 November 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (23) , 2920-2922
Transcatheter Mitral Valve Replacement
- Open Access
- 31 October 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1288278
Case Report: Stretching the limits—late valvuloplasty for THV dysfunction following redo mitral valve-in-valve implantation
Late balloon valvuloplasty can be used to treat under-expansion-related transcatheter heart valve (THV) dysfunction. Whether this can be performed following redo-THV implantation is unknown. Herein, we report a case of a 72-year-old male presenting with symptomatic gradient elevation following redo mitral valve-in-valve implantation. The patient was successfully treated with late balloon valvuloplasty with gradient improvement. In conclusion, late valvuloplasty is effective even with several layers of valves. However, larger studies are required to clarify the role of this approach further.
- 31 October 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1288278
Open AccessCase Report: Stretching the limits—late valvuloplasty for THV dysfunction following redo mitral valve-in-valve implantation
Late balloon valvuloplasty can be used to treat under-expansion-related transcatheter heart valve (THV) dysfunction. Whether this can be performed following redo-THV implantation is unknown. Herein, we report a case of a 72-year-old male presenting with symptomatic gradient elevation following redo mitral valve-in-valve implantation. The patient was successfully treated with late balloon valvuloplasty with gradient improvement. In conclusion, late valvuloplasty is effective even with several layers of valves. However, larger studies are required to clarify the role of this approach further.